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A mega - issueThis month’s edition is larger than usual so that we can
catch up with a backlog of accepted manuscripts. We view
this as a positive sign of receiving increasing numbers of
good manuscripts.
Guidelines are discussed in three articles. McGowan
et al. report on the experience of implementing a world
bank loan to develop a clinical practice guideline program
in Kazakhstan; this was quite complex, given the paucity of
resources in Russian. It is heartening that health systems
foreign aid loans from institutions such as the world bank
to lower/middle income countries now include building
systems for evidence e based decision making.
When developing guidelines, how worried should we be
about accepting the effect size from a single well designed
RCT e should the confidence in this be rated as low?
Gartlehner et al. challenge the results of widely cited papers
(some in this journal), on the ‘proteus phenomenon’, the
greater tendency in science for early replications of a work
to contradict the original findings. Gartlehner found this
was not true in a random sample of 100 Cochrane reviews
that included at least three RCTs across a range of clinical
topics; the exception was where there was a large effect
size in the first trial.
Developing guidelines for reporting case series need
more attention as case series are still clinically important
for a number of situations. Examples are delayed adverse
effects and health technologies that get modified too rapidly
for trials to keep up with them. Bing et al. propose a 20
item checklist; this resulted from a Delphi of experts as-
sessing 105 case series analysed by principal component
analysis followed by an expert panel.
Prediction Rules are addressed in four articles.
A commentary by Steyerberg and Harrell propose a new
combination of internal and external validation steps for the
validation of prediction models that makes the most of
limited sample sizes.
Adoption and clinical use of robustly validated evi-
dence- based clinical decision rules, continues to be a chal-
lenge. Logistics, complexity and lack of transparency are
the most frequent reasons cited for reluctance of clinicians
to use them. Sanders et al. report on the trade-off between
simplifying and the poorer resulting discrimination of sim-
plifying a cardiac decision rule the Emergency Department
Assessment of Chest pain Score (EDACS). It is accepted
that there needs to be external validation of diagnostic
and prognostic indexes before they should be used inhttp://dx.doi.org/10.1016/j.jclinepi.2015.12.001
0895-4356/ 2016 Elsevier Inc. This is an open access article under the CC BYclinical practice; Riley et al. show how multivariate
meta-analysis of individual participant data helped the cal-
ibration of prediction models in cancer and deep vein
thrombosis.
Giovanni studied the added value of multiple testing.
They tackled the problem of how to predict length of stay,
cognitive function and discharge destination [home or insti-
tution] in a cohort of over 300 patients admitted to 10 geri-
atric centres on whom a battery of tests was conducted.
The clinicians’ clinical prediction was accurate for the
extremes of functioning but was poor for those in the
middle e and the battery of tests did not add materially
to this accuracy.
Questionnaires appear to be increasingly applicable. For
example, evidence is accumulating that Patient Reported
Outcomes can be obtained from children as young as six;
Denbaek et al. show over 80% agreement between children
aged 6-14 and parents on reporting illness-related absentee-
ism from school.
However, parsimony e shortening, to minimise the re-
spondent burden on all patients e is critical. But how to
do it? Two papers in this issue address this. Guillemin sug-
gest the following criteria: (1) Document the validity of the
original scale; (2) Take the conceptual model into account;
(3) Preserve content validity; (4) Preserve psychometric
properties; (5) Document the justification for selection of
each item; and (6) Validate the short-form CMS in an inde-
pendent sample. These authors provide a good example of
the challenges in meeting these criteria as applied to the
challenge of shortening (from 43 to 20 items) a composite
outcome Patient Reported Outcome Scale the Mini-
OAKHQOL a disease specific outcome instrument for knee
and hip osteoarthritis; one key aspect, demonstration of the
responsiveness, is still needed.
Quality of life scales need to be easily interpretable if
they are to be useful for providing estimates of the magni-
tude of benefit and harm for practice or policy. Two of the
most widely used QOL Instruments that have been used in
thousands of trials are the SF36 and European Organisation
for Research and Treatment of Cancer [EORTC] QLQ-30
questionnaires-these have 8 and 15 outcomes respectively
and it is recommended that these be reported individually.
The SF36 does have 2 summary component scores Physical
Component Summary Mental Component Score but these
do not perform well psychometrically and the FDA no lon-
ger accepts them as primary/major outcomes in pivotal-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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colleagues utilise best-practice methods that emphasize
the goodness of fit with the different aspects of factor anal-
ysis dimensionality laid out in 8 higher order models. They
conclude that a summary score for the EORTC QLQ-C30 is
robust and can be used.
Statistical and related methods issues are the focus of
five articles. Briel et al. report on a large follow up study
of eight Research Ethics Boards in Switzerland, Germany
and Canada to assess the reasons for early stopping of tri-
als. They found that most discontinuations of clinical trials
were not based on pre-planned interim analyses or stopping
rules; they recommend these be included in all protocols
and reporting guidelines such as CONSORT. Mavridis
et al. using a database of trials in schizophrenia, argue that
network meta-analysis can be used to adjust for both a]
publication bias and b] small-study effects e two major
threats to the validity of meta-analysis.
The area under the curve statistic is the standard for
quantifying the ability of a risk model to discriminate be-
tween individuals who will or will not manifest the out-
come of interest. A risk model with a higher AUC will
be able to better separate the predicted risk distribution
curves of events and non-events. AUC lacks an important
parameter: the incidence of the outcome in the population,
and thus, it is not well suited for clinical decision.
Campbell et al. solve this with use of a new statistic, the
prediction impact curve (PIC)-this estimates the percentage
of events prevented when a risk model is used to assign
high-risk individuals to an intervention; they demonstrate
this with an example. of the prevention of coronary heart
disease.
Competing risk of dying [i.e. the patient dies but not of
the condition of interest; they die instead from another un-
related disease] has been overlooked in many studies in
leading journals; Walraven shows that a third of 100 Kaplan
Meier Risk Estimates in 2013 were biased upwards due to
this. They recommend the use of the cumulative incidence
function to overcome this.
Kollhorst present nice example using previous prescrib-
ing practices to demonstrate the challenge in choosing an
instrument variable to handle confounding by indication.
The World Health Organisation measure of drug expo-
sure Defined Daily Dose is widely used in pharmacoepi-
demiology studies; Sinnott et al. show that it will result
in underestimation and overestimation of association with
harms and advocate the ‘days supply’ as being more
accurate.
Research wastage is becoming a recurring theme in JCE.
The evidence of ongoing ‘research wastage’ continues to
accumulate. Extra attention to this needed. Sawin et al. car-
ried out an in 2011 update of their 2004 study that showed
that 70-75% of trials fail to be cited in subsequent trials and
that this is more often the negative trials that are missing.
This is despite the updated CONSORT statement recom-
mendation that new results be set within the context ofthe existing evidence. Biased and inadequate citation of pri-
or research in reports of cardiovascular trials is a continuing
source of waste in research.
Observational studies are the focus of four studies: Col-
lecting data in longitudinal cohort studies is expensive and
there is little guidance published on methods of optimal
‘cost-efficiency’ regarding when and how often to collect
data. Using data from the East-West study, the Finnish part
of the Seven Countries Study of cardiovascular epidemiol-
ogy, Reinikainen et al. describe the data and modelling used
to show that most items only need collecting every
10 years.
As precision medicine combines the study of both the
genotype and phenotype, Mendelian randomisation needs
to be better understood to appreciate the increasingly com-
mon problem of type 1 errors in genetics studies. As
Burgess et al. state ‘‘There is a distinction between Mende-
lian randomization as it was initially conceived and per-
formed (mainly for circulating biomarkers using few
genetic variants in relevant gene regions) and how it is
often used today (often opportunistically using large num-
bers of genetic variants whose functional relevance is un-
known)’’.. In order to filter out the large numbers of false
positive statistically significant [often highly so] associa-
tions they propose using an adaptation of the classic Doll
and Hill criteria for causation- that will surely be reassuring
to clinical epidemiologists as a nice change from the jargon
in genetic studies.
Powels et al. show that the quality of reporting of con-
founding in leading epidemiology and general medicine
journals, has improved only marginally 3-5 years after the
publication of the STROBE guideline. The authors suggest
that authors be required to submit a completed checklist
and be expected to carry out quantitative bias analysis for
unmeasured confounding.
RCTs and their variants are the focus of four articles. A
new term ‘In silico’ is introduced for the first time to a JCE
title in this issue e it means ‘performed on computer or via
computer simulation’; Wikipedia tells us the phrase was
coined in 1989 as an allusion to the Latin phrases
in vivo, in vitro, and in situ, which are commonly used in
biology (see also systems biology) and refer to experiments
done in living organisms, outside of living organisms, and
where they are found in nature, respectively. Using the ex-
ample of sumatriptin trials for migraine headaches,
Chabaud et al. report on the use of a RCTs model with
100,000 Monte Carlo repetitions to generate a treatment ef-
fect in a virtual population of patients obtained after mod-
eling human behavior, disease progress, and drug effects
using specific mathematical models and numerical meth-
ods. Virtual patients are then randomized in virtual trials
considering different designs to allow comparisons of esti-
mated power, accuracy of the estimation of treatment ef-
fect, and number of patients receiving active treatment.
They compared (A) Parallel, (B) crossover, (C) randomized
withdrawal, (D) early escape, (E) play the winner, (F) drop
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ers views on this.
Estellat et al. conducted an innovative ethics exercise to
ask a panel of independent rheumatologists whether patient
profiles derived from real patients selected from the control
group of trials of biologics in rheumatoid arthritis were
being denied available alternative efficacious therapy.
70% of the patients in the background therapy plus placebo
control groups were deemed to be receiving substandard
care but these respondents would be prepared to enter half
of these same patients into a trial. This raises important as-
pects of the trade-off between the demands for placebo e
controlled trials by approval agencies versus the ethical
equipoise in enrolling such patients.
Sample size calculations for stepped wedge and cluster
randomised trials are complex and often wrong. Using a
new formula, Hemming and Taljaard provide a simpler
way of calculating these with useful tables.
Clarke et al. showed that the RCT design can be used to
assess the reliability of peer review. Such studies are impor-
tant since peer review, like democracy, is not ideal but still
seems the fairest way we have to make tough choices in sci-
ence. So it is reassuring to see the high reliability of grant
funding decisions in fellowships for early career researchers
in their randomised trial. As systematic reviews are increas-
ingly used as representing the state of knowledge, assessing
and avoiding risk of bias in reviews deserves high priority.
Whiting et al. present a new generic risk-of-bias tool
ROBIS systematic reviews of aetiology, diagnosis, inter-
ventions and prognosis. Several tools exist for undertaking
critical appraisal and quality assessment of systematic re-
views but none specifically aim to assess the risk of bias
in systematic reviews; the ROBIS tool was designed to fill
this gap in risk of bias assessment. This now needs to be
evaluated for its usability and usefulness by the different
audiences it is aimed at, namely guideline developers, au-
thors of overviews of systematic reviews (‘‘reviews of re-
views’’), and review authors who might want to assess or
avoid risk of bias in their reviews.
Not all systematic reviews are equal! Seehra et al. re-
viewed over 300 systematic reviews published in the Core
Clinical Journals in 2014. They found that although some as-
sessment of risk of bias was carried out in over 70%, rarely
was a decisionmade to include only the better designed stud-
ies e which casts serious doubt on accuracy and usefulness
of the effect size, however carefully computed.Many teachers of clinical epidemiology still favour
NNTB and NNTH [Number needed to treat for benefit/
harm] as a good way of communicating the effect size of
interventions and this remains a core element in CAML
[Critical Appraisal of the Medical Literature]. In addition
to the influence of prevalence, the reader needs to pay at-
tention to the accuracy of estimates of the outcome
[CAML]; van Werkhoven et al. provide a nice example of
what happens when outcomes are missed, and the substan-
tive effect upon the NNTB /NNTH when identifying
Community Acquired Pneumonia episodes in a
population-based pneumococcal vaccination trial.
Presentation of results of complex interventions is not
easy e Hutchings et al. using the exemplar of two gastro-
intestinal complex interventions [modernising endoscopy
services using 10 different qualitative and quantitative re-
search methods; an RCT comparing the clinical and cost-
effectiveness of doctors and nurses undertaking upper and
lower GI endoscopy in 23 endoscopy units], present a nice
clean and clear way of presenting the different conclusions
to the different stakeholders e with separate summary ta-
bles for patients, providers, and health system managers.
It would be interesting to extend this to providing separate
Summary of Findings Tables in Cochrane Reviews for dif-
ferent stakeholders.
Reporting and methodological quality of 197 published
surgical meta-analyses found in Medline in 2013 was found
to be quite variable with few satisfying g the PRISMA and
AMSTAR criteria; it was reassuring to see the correlation
between the scores on the two scales achieved a R2 of
0.79 suggesting that the same attributes are being assessed
by each.
Many organisations have spent large amounts on moving
to a paper e free environment but the clinical and laboratory
systems do not harmonise. Lim Faye et al. provide an ex-
ample of pediatric infections in a hospital that demonstrate
the potentially harmful pitfalls of incomplete data integra-
tion where 30% of microbiological tests never made it onto
the patients health record. Validation should be required
when introducing of any such system both for clinical care
and research.Peter Tugwell
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